Our results indicate a pivotal role for TGF-β in the tumour localised evasion of human NK cells and demonstrate that the suppressive effects of this cytokine on NK cell effector function can be reversed using TGF-β antagonists in wholly autologous, patient-derived systems ex vivo. The gene discussed is TGFB1; the disease is neoplasm.